[en] Matrix metalloproteinases (MMPs) are group of enzymes thought to play an important role in trophoblastic and tumor invasion. The aim of our study was to investigate the trophoblastic expression of MMPs and p53 in normal trophoblast and hydatidiform moles (HM). Paraffin sections of 45 specimens, including 14 complete hydatidiform moles (CM), 15 partial hydatidiform moles (PM), 8 atypical partial hydatidiform moles (aPM), and 8 controls were selected. Classification of HM was established on histologic criteria and supported by the DNA ploidy results. Tissue sections from each case were immunostained with monoclonal antibodies, cytokeratin-7, MMP-2, MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1, and p53 wild type (p53wt) and mutant types (mutp53). Staining for cytokeratin-7 revealed a positive reaction in 93% of the samples. MMP-2 was mainly expressed in the syncytiotrophoblast of HM and found in 62% of aPM, 60% PM, and 93% CM. The mutp53 was mainly and focally expressed in syncytiotrophoblastic cells and was found in 63% of aPM, 80% PM, and 93% CM. Expression of MMP-2 and mutp53 was both significantly greater in HM vs control group (P < 0.05) and greater in CM vs PM and aPM (P < 0.05). No significant difference was observed for cytokeratin-7, MMP-9, TIMP-1, and p53wt between the HM subgroups and between HM and control group. MMP-2 and mutp53 are overexpressed in HM as compared with normal trophoblast and might participate in the invasive behavior of the HM.
Disciplines :
Oncology Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Petignat, P.
Laurini, R.
Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
Bruchim, I.
Bischof, P.
Language :
English
Title :
Expression of matrix metalloproteinase-2 and mutant p53 is increased in hydatidiform mole as compared with normal placenta
Publication date :
2006
Journal title :
International Journal of Gynecological Cancer
ISSN :
1048-891X
eISSN :
1525-1438
Publisher :
Blackwell Science, Malden, United States - Massachusetts
Bischof P, Meisser A, Campana A. Paracrine and autocrine regulators of trophoblast invasion-a review. Placenta 2000;21(Suppl. A):S55-S60.
Bischof P, Martelli M, Campana A, Itoh Y, Ogata Y, Nagase H. Importance of matrix metalloproteinases in human trophoblast invasion. Early Pregnancy 1995;1:263-9.
Librach CL, Werb Z, Fitzgerald ML et al. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol 1991;113:437-49.
Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980;1:3-19.
Bischof P, Meisser A, Campana A. Mechanisms of endometrial control of trophoblast invasion. J Reprod Fertil Suppl 2000;55:65-71.
Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Inter-action of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992;267:4583-91.
Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: two entities. A morphologic and cytogenetic study with some clinical consideration. Am J Obstet Gynecol 1977;127:167-70.
Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evolution of the complete and partial mole. Am J Obstet Gynecol 1978;132:20-7.
Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978;131:665-71.
Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med 1996;335:1740-8.
Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975;36:863-6.
Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med 1994;39:155-62.
Seckl MJ, Fisher RA, Salerno G et al. Choriocarcinoma and partial hydatidiform moles. Lancet 2000;356:36-9.
Meyer E, Vollmer JY, Bovey R, Stamenkovic I. Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 2005;65:4261-72.
Hedley DVV, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 1981;75:816-21.
Bischof P, Irminger-Finger I. The human cytotrophoblastic cell, a mononuclear chameleon. Int J Biochem Cell Biol 2005;37:1-16.
Sequoia Ecosystem and Recreation Preserve Act of 1999. In 106th Congress ed.; 1999.
Vegh GL, Selcuk Tuncer Z, Fulop V, Genest DR, Mok SC, Berkowitz RS. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta. Gynecol Oncol 1999;75:248-53.
Okamoto T, Niu R, Yamada S, Osawa M. Reduced expression of tissue inhibitor of metalloproteinase (TIMP)-2 in gestational trophoblastic diseases. Mol Hum Reprod 2002;8:392-8.
Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001;277:15-30.
Al-Bozom IA. p53 and Bcl-2 oncoprotein expression in placentas with hydropic changes and partial and complete moles. APMIS 2000;108:756-60.
Chen CA, Chen YH, Chen TM et al. Infrequent mutation in tumor suppressor gene p53 in gestational trophoblastic neoplasia. Carcinogenesis 1994;15:2221-3.
Cheung AN, Shen DH, Khoo US et al. Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: correlation with mdm2, proliferation index, and clinicopathologic parameters. Int J Gynecol Cancer 1999;9:123-30.
Cheung AN, Srivastava G, Chung LP et al. Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal human placentas. J Reprod Med 1994;39:223-7.
Fulop V, Mok SC, Genest DR, Gati I, Doszpod J., Berkowitz RS. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998;43:119-27.
Halperin R, Peller S, Sandbank J, Bukovsky I, Schneider D. Expression of the p53 gene and apoptosis in gestational trophoblastic disease. Placenta 2000;21:58-62.
Uzunlar AK, Yilmaz F, Bayhan G, Akkus Z. Expressions of p53, proliferating cell nuclear antigen, and Ki-67 in gestational trophoblastic diseases. Eur J Gynaecol Oncol 2002;23:79-83.
Wu Y, Zhang Q, Tang H. [Detection of p53 gene mutations in human gestational trophoblastic neoplasia by polymerase chain reaction-single strand conformational polymorphism techniques] [Chinese]. Hunan Yi Ke Da Xue Xue Bao 1997;22:338-40.
Persaud V, Ganjei P, Nadji M. Cell proliferative activity and mutation of P53 suppressor gene in human gestational trophoblastic disease. West Indian Med J 1993;42:142-3.
Shi YF, Xie X, Zhao CL et al. Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours. Br J Cancer 1996;73:1216-9.
Rogel A, Popliker M, Webb CG., Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 1985;5:2851-5.
Lane DP, Benchimol S. p53: oncogene or anti-oncogene?. Genes Dev 1990;4:1-8.
Webley KM, Shorthouse AJ, Royds JA. Effect of mutation and conformation on the function of p53 in colorectal cancer. J Pathol 2000;191:361-7.